News Article

The US government has a renewed focus on pharma tariffs. Beneath the political narrative, US pharma tariffs have progressed beyond a tactical trade lever and are becoming a market-defining mechanism, shaping which manufacturers retain control, margin, and resilience.

Candesic has built a detailed investor framework mapping who stands to gain – and who is at risk of top line and margin erosion as tariffs, pricing policy and reshoring converge.

Click the link to download our analysis which includes:

• What is driving the shift
• The use of tariffs as both a negotiation tool and structural lever
• A strategic outlook on the future for pharma tariffs
• Implications for private investment

If you would like to speak to the authors, feel free to reach out to Candesic partner Aldous Mitchell, engagement manager Blake Edwards or senior associate Dr Campbell Foubister.